Multiple sclerosis (MS) is an autoimmune disease triggered by environmental factors that act
on a genetically susceptible host. It features three clinical stages: a pre-clinical stage …

The treatment landscape for relapsing forms of multiple sclerosis (RMS) has expanded
considerably over the last 10 years with the approval of multiple new disease-modifying …

Purpose Although cerebral perfusion alterations have long been acknowledged in multiple
sclerosis (MS), the relationship between measurable perfusion changes and the status of …

Introduction: Advances in magnetic resonance imaging (MRI) technology and analyses are
improving our understanding of the pathophysiology of multiple sclerosis (MS). Due to their …

Despite the availability of multiple disease-modifying therapies for relapsing multiple
sclerosis (MS), there remains a need for highly efficacious targeted therapy with a favorable …

Daclizumab (Zinbryta®; previously known as daclizumab high-yield process) is a
therapeutic monoclonal antibody that has recently been approved for the treatment of …

Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple
sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals …

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system
(CNS), characterized by inflammation and demyelination. Presently, repeated relapses of …

Relapsing multiple sclerosis (RMS) presents a highly variable clinical evolution among
patients, and its management should be personalized. Although there is no cure at present …

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-
documented monographs on drugs that are newly released or are in late phase 3 trials. The …